Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR

Genes Chromosomes and Cancer

Volumn 53, Issue 12, 2014, Pages 1033-1040

  Peraldo Neia, Caterina ^a   Cavalloni, Giuliana ^b   Balsamo, Antonella ^c   Venesio, Tiziana ^c   Napoli, Francesca ^a   Sassi, Francesco ^a   Martin, Vittoria ^d   Frattini, Milo ^d   Aglietta, Massimo ^a,b   Leone, Francesco ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b Fondazione del Piemonte per l'Oncologia   (Italy)

^c Unit of Pathology   (Italy)

^d Institute of Pathology   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FIG-ROS1 FUSION PROTEIN, HUMAN; ONCOPROTEIN;

BILE DUCT TUMOR; CARCINOMA; GENETICS; HUMAN; PATHOLOGY; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

BILE DUCT NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; HUMANS; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 84907948624     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22212     Document Type: Article

References (38)

1. Arai Y, Totoki Y, Takahashi H, Nakamura H, Hama N, Kohno T, Tsuta K, Yoshida A, Asamura H, Mutoh M, Hosoda F, Tsuda H, Shibata T. 2013. Mouse model for ROS1-rearranged lung cancer. PLoS One 8:e56010.
2. Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. 2011. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 29:2357-2363.
3. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ. 2012. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863-870.
4. Birch AH, Arcand SL, Oros KK, Rahimi K, Watters AK, Provencher D, Greenwood CM, Mes-Masson AM, Tonin PN. 2011. Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. PLoS One 6:e28250.
5. Birchmeier C, Birnbaum D, Waitches G, Fasano O, Wigler M. 1986. Characterization of an activated human ros gene. Mol Cell Biol 6:3109-3116.
6. Birchmeier C, Sharma S, Wigler M. 1987. Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci USA 84:9270-9274.
7. Charest A, Kheifets V, Park J, Lane K, McMahon K, Nutt CL, Housman D. 2003a. Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma. Proc Natl Acad Sci USA 100:916-921.
8. Charest A, Lane K, McMahon K, Park J, Preisinger E, Conroy H, Housman D. 2003b. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer 37:58-71.
9. Charest A, Wilker EW, McLaughlin ME, Lane K, Gowda R, Coven S, McMahon K, Kovach S, Feng Y, Yaffe MB, Jacks T, Housman D. 2006. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res 66:7473-7481.
10. Davare MA, Saborowski A, Eide CA, Tognon C, Smith RL, Elferich J, Agarwal A, Tyner JW, Shinde UP, Lowe SW, Druker BJ. 2013. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc Natl Acad Sci USA 110:19519-19524.
11. Davies KD, Doebele RC. 2013. Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res 19:4040-4045.
12. Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC. 2012. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 18:4570-4579.
13. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L, Wallis J, Chen K, Walker J, McDonald S, Bose R, Ornitz D, Xiong D, You M, Dooling DJ, Watson M, Mardis ER, Wilson RK. 2012. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150:1121-1134.
14. Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K, Roka R, Freimann-Pircher S, Gruenberger T. 2010. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: A phase 2 study. Lancet Oncol 11:1142-1148.
15. Gu TL, Deng X, Huang F, Tucker M, Crosby K, Rimkunas V, Wang Y, Deng G, Zhu L, Tan Z, Hu Y, Wu C, Nardone J, MacNeill J, Ren J, Reeves C, Innocenti G, Norris B, Yuan J, Yu J, Haack H, Shen B, Peng C, Li H, Zhou X, Liu X, Rush J, Comb MJ. 2011. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6:e15640.
16. Isa T, Tomita S, Nakachi A, Miyazato H, Shimoji H, Kusano T, Muto Y, Furukawa M. 2002. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 49:604-608.
17. Jun HJ, Johnson H, Bronson RT, de Feraudy S, White F, Charest A. 2012. The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation. Cancer Res 72:3764-3774.
18. Kang YK, Kim WH, Lee HW, Lee HK, Kim YI. 1999. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest 79:477-483.
19. Lee J, Lee SE, Kang SY, Do IG, Lee S, Ha SY, Cho J, Kang WK, Jang J, Ou SH, Kim KM. 2013. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer 119:1627-1635.
20. Leone F, Cavalloni G, Pignochino Y, Sarotto I, Ferraris R, Piacibello W, Venesio T, Capussotti L, Risio M, Aglietta M. 2006. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res 1:1680-1685.
21. Liu P, Wu Y, Sun L, Zuo Q, M S. 2013. ROS kinase fusions are not common in Chinese patients with cholangiocarcinoma. J Cent South Univ 33:474-478.
22. Matsushime H, Wang LH, Shibuya M. 1986. Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule. Mol Cell Biol 6:3000-3004.
23. Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F. 2010. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 10:631-645.
24. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb MJ. 2007. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190-1203.
25. Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, Mack JS, Silver MR, Zhou X, Haack H. 2012. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 18:4449-4457.
26. Saborowski A, Saborowski M, Davare MA, Druker BJ, Klimstra DS, Lowe SW. 2013. Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. Proc Natl Acad Sci USA 110:19513-19518.
27. Saetta AA, Papanastasiou P, Michalopoulos NV, Gigelou F, Korkolopoulou P, Bei T, Patsouris E. 2004. Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. Virchows Arch 445:179-182.
28. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, Lee J, Jung YJ, Kim JO, Yu SB, Kim J, Lee ER, Kang CH, Park IK, Rhee H, Lee SH, Kim JI, Kang JH, Kim YT. 2012. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 22:2109-2119.
29. Shaw A, Camidge D, Engelman J, Solomon B, Kwak E, Clark J, Salgia R, Shapiro G, Bang Y, Tan W, Tye L, Wilner K, Stephenson P, Varella-Garcia M, Bergethon K, Iafrate A, Ou S. 2012. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. 2012 ASCO Annual Meeting, Vol 30 No 15 suppl (May 20 Supplement), Abstract No 7508. J Clin Oncol.
30. Shaw AT, Hsu PP, Awad MM, Engelman JA. 2013. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 13:772-787.
31. Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, Kimura Y, Drilon A, Guha U, Rusch V, Kris MG, Zakowski MF, Rizvi N, Khanin R, Ladanyi M. 2012. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 18:6599-6608.
32. Suto T, Habano W, Sugai T, Uesugi N, Funato O, Kanno S, Saito K, Nakamura S. 2000. Aberrations of the K-ras, p53, and APC genes in extrahepatic bile duct cancer. J Surg Oncol 73:158-163.
33. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y. 2012. RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378-381.
34. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, Wittekind C. 2003. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52:706-712.
35. Tsuda H, Satarug S, Bhudhisawasdi V, Kihana T, Sugimura T, Hirohashi S. 1992. Cholangiocarcinomas in Japanese and Thai patients: Difference in etiology and incidence of point mutation of the c-Ki-ras proto-oncogene. Mol Carcinog 6:266-269.
36. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, Investigators A-T. 2010. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273-1281.
37. Weickhardt AJ, Nguyen T, Paskulin D, Le A, Aisner D, Schulte N, Chionh F, Mariadason J, Tebbutt N, Doebele R, M V-G. 2013. ALK and ROS gene rearrangements detected in colorectal cancer (CRC) by fluorescence in situ hybridization (FISH). 2013 ASCO Annual Meeting, Vol 31, No 15 suppl (May 20 Supplement), Abstract N 3545. J Clin Oncol 2013.
38. Xu RF, Sun JP, Zhang SR, Zhu GS, Li LB, Liao YL, Xie JM, Liao WJ. 2011. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. Biomed Pharmacother 65:22-26.